Adam's Legal Newsletter β’ 499 implied HN points β’ 28 Mar 24
- Plaintiffs in the case lack standing, which weakens their argument. They need to show personal harm, not just philosophical opposition.
- Even if plaintiffs had standing, their claims fail on the merits. The FDA's decisions were well-reasoned and based on evidence, debunking plaintiffs' objections.
- Banning mifepristone won't help the plaintiff-doctors study it; rather, it will hinder data collection. The FDA's evaluation of studies appears rational and reasonable.